Ultimately, prospective studies are warranted to determine whether co-existing ARID1A loss, TP53 dysfunction, or oncogene-induced RS can guide the clinical deployment of ATRis either as monotherapy or in rational combination regimens within the gastric cancer landscape [119,124,130,131,132]. The gene discussed is TP53; the disease is gastric cancer.